Evidence map›Paper›PMID 33486597›Full record

ArticleClinical rheumatology2021

How do patients define Raynaud's phenomenon? Differences between primary and secondary disease.

Susan L Murphy, Alain Lescoat, Mary Alore, Michael Hughes, John D Pauling, Maya Sabbagh, Dinesh Khanna

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Susan L MurphyDepartment of Physical Medicine and Rehabilitation, University of Michigan, 24 Frank Lloyd Wright Drive, Lobby M Suite 3100, Ann Arbor, MI, 48105, USA. sumurphy@umich.edu.ORCID http://orcid.org/0000-0001-7924-0012
Alain LescoatDepartment of Internal Medicine and Clinical Immunology, CHU Rennes, University of Rennes 1, Rennes, France.
Mary AlorePeer Mentors Program, University of Michigan Scleroderma Program, 7C27 NIB 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.
Michael HughesDepartment of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
John D PaulingRoyal National Hospital for Rheumatic Diseases (at Royal United Hospitals), Bath, UK.
Maya SabbaghPeer Mentors Program, University of Michigan Scleroderma Program, 7C27 NIB 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.
Dinesh KhannaDepartment of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, 7C27 NIB 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.ORCID https://orcid.org/0000-0003-1412-4453
University of Michigan · USInserm · FRRoyal Hallamshire Hospital · GBRoyal National Hospital for Rheumatic Diseases · GB

Funding

Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
Systemic Sclerosis-Associated Interstitial Lung Disease Response IndexR01AR070470 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2017 to 2019
$642k
Syk blockade in bullous skin diseasesR43AR063129 · NIAMS · PORTOLA PHARMACEUTICALS, INC. · PI SINHA, UMA · 2012 to 2012
$298k
Hôpitaux Universitaire du Grand Ouest AAP JCM2020NIAMS NIH HHS K24 AR063120NIAMS NIH HHS K24-AR-063129NIAMS NIH HHS R01 AR070470NIAMS NIH HHS R43 AR063129Rennes University Hospital CORECT Visiting Grant 2020
6 · The paper itself

Abstract

INTRODUCTION/

objectivesTo examine how people define Raynaud's phenomenon (RP) based on their lived experiences and explore if differences exist depending on primary or secondary RP diagnosis.

methodAn international survey was sent to people with RP through health systems, foundations, and social media. Qualitative coding of responses to an open text question regarding one's own definition of RP was performed and themes were identified. The prevalence of themes among the sample and then comparisons between themes among people who self-reported primary versus secondary diagnosis of RP were performed.

resultsThere were 1345 respondents from 45 countries (mean age 51.5 years, 93% female) who defined RP in their own words; 17% reported primary RP and 83% reported secondary RP (69% of secondary RP was scleroderma-related, n = 927). Over half defined their RP by describing the body parts affected, color changes, pain, and triggers or situations in which an episode occurs. Patients with primary RP more frequently defined RP in terms of its impact on function/quality of life and pain compared to those with secondary RP (34.5% versus 25.3%, respectively, p=0.004; 54.0% versus 46.8%, p=0.05). Patients with secondary RP more frequently included specific body parts, color change, the management of attacks, and other digital vascular complications in their definition of RP.

conclusionsWe have identified differences in how people with primary and secondary RP define RP, in terms of how they feel and function. Our findings have implications for the domains of outcome measures for assessing RP within different patient populations. Key Points • Pain is more often mentioned in primary RP and color change in secondary RP. • Over 25% of patients included reduced the quality of life as part of their RP definition. • The concept of "attack" is used to define RP by only 2% of patients.

Indexed as

Raynaud DiseaseScleroderma, LocalizedScleroderma, SystemicFemaleHumansMaleMiddle AgedQuality of LifeSurveys and QuestionnairesConnective tissue diseasesQualitative analysisRaynaud’s phenomenonSclerodermaSystemic sclerosis

Identifiers

PMID33486597
PMCPMC8080278
OpenAlexW3123137146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.